Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

Key facts

Sponsor

Zymenex A/S

Principal Investigator

Allan M. Lund, MD

Department of Clinical Genetics, Juliane Marie Centre, Region Hovedstaden, Copenhagen University hospital, Denmark

Intervention

Lamazym(drug)

Enrollment

10 enrolled

Eligibility

5-21 years · All sexes

Timeline

2011 – 2012

Study locations (1)

• Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark

Collaborators

European Commission

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Alpha-mannosidosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06184503
  Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
  Chiesi Farmaceutici S.p.A.

See all trials for Alpha-mannosidosis →